| Autor: |
Roberto Kalil Filho, Ana Paula H. Yokoyama, Edison Luiz Durigon, Rafael Rahal Guaragna Machado, Luiz Vicente Rizzo, Araci M. Sakashita, Luiz F. L. Reis, Danielle Bastos Araujo, Laerte Pastore, Roberta Fachini, Carolina Bonet-Bub, Fernando Blumm, M. Assuncao, Victor Nudelman, Mariane T. Amano, Alexandre R Marra, Rita Fontão-Wendel, Valeria F. Dutra, Jose Mauro Kutner, Anamaria A. Camargo, Ana Paula F. Dametto, Alfredo Salim Helito, João Renato Rebello Pinho, Esper G. Kallas, Patricia Scuracchio, Nelson Hamerschlak, Ruth Achkar, Silvano Wendel, Carlos Roberto Ribeiro de Carvalho, Gabriela Candelaria, Mirian Dal Ben |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Transfusion |
| ISSN: |
1537-2995 |
| Popis: |
Background Current evidence regarding COVID‐19 convalescent plasma (CCP) transfusion practices is limited and heterogeneous. We aimed to determine the impact of the use of CCP transfusion in patients with previous circulating neutralizing antibodies (nAbs) in COVID‐19. Methods Prospective cohort including 102 patients with COVID‐19 transfused with ABO compatible CCP on days 0–2 after enrollment. Clinical status of patients was assessed using the adapted World Health Organization (WHO) ordinal scale on days 0, 5, and 14. The nAbs titration was performed using the cytopathic effect‐based virus neutralization test with SARS‐CoV‐2 (GenBank MT126808.1). The primary outcome was clinical improvement on day 14, defined as a reduction of at least two points on the adapted WHO ordinal scale. Secondary outcomes were the number of intensive care unit (ICU)‐free days and the number of invasive mechanical ventilation‐free days. Results Both nAbs of CCP units transfused (p |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Plný text 